Focus:

Medical Devices, Therapeutics, Diagnostics and Auxiliary Technologies

Type:

Development and expansion capital funding clinical trials and commercialisation.

Geography:

Australia, New Zealand and Asia Pacific

Committed Capital:

Target A$200 million

Investment Strategy:

Active investment in later stage Asia Pacific healthcare and medical science companies, targeting outstanding technologies in clinical trial and commercialisation stage that offer international commercial opportunity and what the Manager believes will be superior investment returns at reduced risk.